Novartis’ Beovu safety woes could cost billions of dollars, says analystThe launch of Novartis’ Beovu ophthalmology drug could be compromised after a safety warning from doctors over several Share XNovartis’ Beovu safety woes could cost billions of dollars, says analysthttps://pharmaphorum.com/news/novartis-beovu-launch-could-be-hit-by-safety-warning/
More pressure on Bayer as EU approves Novartis’ Beovu in wet AMDThe market for ophthalmology drugs in Europe just got hotter with the approval of Novartis’ Beovu for neovascular Share XMore pressure on Bayer as EU approves Novartis’ Beovu in wet AMDhttps://pharmaphorum.com/news/more-pressure-on-bayer-as-eu-approves-novartis-beovu-in-wet-amd/
Verily plans digital ophthalmology joint venture with SantenVerily is planning a digital ophthalmology joint venture with Japan’s specialist in the field, Santen. The joint venture Share XVerily plans digital ophthalmology joint venture with Santenhttps://pharmaphorum.com/news/verily-plans-ophthalmology-joint-venture-with-santen/
ViGeneron to develop next-gen eye gene therapies after funding roundGermany’s ViGeneron is to advance development of its next-generation ophthalmology gene therapy pipeline after a series A financing Share XViGeneron to develop next-gen eye gene therapies after funding roundhttps://pharmaphorum.com/news/vigeneron-to-develop-next-gen-eye-gene-therapies/
Biogen signs marketing deal for two ophthalmology biosimilarsBiogen has gained rights to market two potential ophthalmology biosimilars in major markets including the US, Europe and Share XBiogen signs marketing deal for two ophthalmology biosimilarshttps://pharmaphorum.com/news/biogen-signs-marketing-deal-for-two-ophthalmology-biosimilars/
Scientists hail digital retina heat management breakthroughIt’s common knowledge that managing heat is one of the biggest problems in computer chip design – but Share XScientists hail digital retina heat management breakthroughhttps://pharmaphorum.com/news/scientists-hail-digital-retina-heat-management-breakthrough/
Novartis’ new eye drug undercuts Bayer’s rival with fewer injectionsThe FDA has approved Novartis’s new eye drug brolucizumab for wet age-related macular degeneration, which will match Bayer’s Share XNovartis’ new eye drug undercuts Bayer’s rival with fewer injectionshttps://pharmaphorum.com/news/novartis-new-eye-drug-undercuts-bayers-rival-with-less-frequent-dosing/
NHS funds eye gene therapy, after Novartis cuts £613,000 priceNICE has recommended the NHS should fund Novartis’ Luxturna for a rare eye disorder, after the company agreed Share XNHS funds eye gene therapy, after Novartis cuts £613,000 pricehttps://pharmaphorum.com/news/nhs-funds-eye-gene-therapy-after-novartis-cuts-613000-price/
Could Kyowa Kirin be eyeing ophthalmology use for cancer drug tivozanib?Kyowa Kirin has bought back rights outside of cancer to tivozanib, amending an agreement dating back to 2006 Share XCould Kyowa Kirin be eyeing ophthalmology use for cancer drug tivozanib?https://pharmaphorum.com/news/could-kyowa-kirin-be-eyeing-ophthalmology-use-for-cancer-drug-tivozanib/
